PEDIATRICS Vol. 98 No. 3 September 1996, pp. 514-515
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R.
Right arrow Articles by Elbourne, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R.
Right arrow Articles by Elbourne, D.

Letter To The Editor

Ros Jones 1 and Diana Elbourne 1

1 Perinatal Trials Service, NPEU, Radcliffe Infirmary, Oxford, England OX2 6HE

Our 3-year follow-up study1 was initiated for precisely the reasons cited by Frank and Lecuona (ie, to go beyond the neonatal period to assess the longer term effects of dexamethasone). This is particularly so in the stratum in which there was little neonatal benefit (ie, those infants not ventilator-dependent at the time of dexamethasone/placebo administration). But it is not true to say that there were no beneficial effects of dexamethasone; in the stratum of infants who were ventilator-dependent at trial entry, dexamethasone significantly reduced the length of time they spent on the ventilator, as well as suggesting a tendency to reduce the time spent on supplemental oxygen and in hospital.